Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01824875 · ClinicalTrials.gov registry record · Phase 2
Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors
A Phase 2 study of Insulinoma and Gastrinoma, sponsored by ECOG-ACRIN Cancer Research Group.
- Active
- Registry status
- Phase 2
- Development phase
- 144
- Enrollment target
- 20
- Study locations
NCT01824875 is a Phase 2 study of Insulinoma and Gastrinoma that is active but no longer recruiting, run by ECOG-ACRIN Cancer Research Group. The registered enrollment target is 144 participants, below the 392-participant average among 5 other Insulinoma trials with a reported enrollment target (63% lower). The trial reports 20 study locations across 1 state.
The verdict
NCT01824875, a Phase 2 study of Insulinoma and Gastrinoma, is active but no longer recruiting, sponsored by ECOG-ACRIN Cancer Research Group.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 144 participants
- Enrollment target
- 20
- Study locations
Study Summary
This randomized phase II trial studies how well giving temozolomide with or without capecitabine works in treating patients with advanced pancreatic neuroendocrine tumors. Drugs used in chemotherapy, such as temozolomide and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether temozolomide is more effective with or without capecitabine in treating patients with advanced pancreatic neuroendocrine tumors.
Conditions Studied
Interventions
- DRUG temozolomide
- DRUG capecitabine
Study Locations (20)
California
- Kaiser Anaheim Medical Center - Anaheim
- Kaiser Permanente-Deer Valley Medical Center - Antioch
- Kaiser Permanente Medical Group - Baldwin Park - Baldwin Park
- Kaiser Foundation Hospital - Bellflower
- Alta Bates Summit Medical Center-Herrick Campus - Berkeley
- Mills - Peninsula Hospitals - Burlingame
- Kaiser Permanente Hospital - Fontana
- Kaiser Permanente, Fremont - Fremont
- Kaiser Permanente - Fresno
- Kaiser Permanente - Harbor City - Harbor City
- Kaiser Permanente, Hayward - Hayward
- Southern California Permanente Medical Group - Irvine
- Kaiser Permanente Los Angeles Medical Center - Los Angeles
- University of Southern California/Norris Cancer Center - Los Angeles
- Kaiser Permanente-West Los Angeles - Los Angeles
- Cedars-Sinai Medical Center - Los Angeles
- Kaiser Permanente-Modesto - Modesto
- Sutter Cancer Research Consortium - Novato
- Kaiser Permanente-Oakland - Oakland
- University of California Medical Center At Irvine-Orange Campus - Orange
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 144 participants |
| Start Date | 2013-08-08 |
| Est. Completion | 2026-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01824875
The ClinicalTrials.gov registry entry for NCT01824875 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 144 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 392-participant average among 5 other Insulinoma trials with a reported enrollment target (63% lower). The listed sponsor is ECOG-ACRIN Cancer Research Group, which has 75 total studies on file at ClinicalTrials.gov.
The record links to 7 conditions, with Insulinoma appearing as the primary indexed condition, and to 2 interventions - of which temozolomide is the first listed.
NCT01824875 reports 20 study locations spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT01824875 about?
NCT01824875 is a clinical study titled "Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors". This randomized phase II trial studies how well giving temozolomide with or without capecitabine works in treating patients with advanced pancreatic neuroendocrine tumors. Drugs used in chemotherapy, such as temozolomide and capecitabine, work in different ways to stop the growth of tumor cells, eit...
What is the current status of trial NCT01824875?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 144 participants. The study started on 2013-08-08. Estimated completion is 2026-12.
What conditions does trial NCT01824875 study?
This clinical trial studies the following conditions: Insulinoma, Gastrinoma, Glucagonoma, Pancreatic Polypeptide Tumor, Recurrent Islet Cell Carcinoma.
What interventions are being tested in trial NCT01824875?
The interventions under investigation include: temozolomide (DRUG), capecitabine (DRUG).
Who is sponsoring clinical trial NCT01824875?
This trial is sponsored by ECOG-ACRIN Cancer Research Group, which has 75 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01824875 being conducted?
This trial has 20 study locations across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Insulinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors
COMPLETED · Phase 2
-
Diagnosing and Treating Low Blood Sugar Levels
RECRUITING
-
Fluorodopa F 18 in Congenital Hyperinsulinism and Insulinoma
RECRUITING · Phase 1
-
Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors
COMPLETED · Phase 1
-
Laparoscopy to Remove Pancreatic Tumors (Insulinomas)
COMPLETED · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.